List view / Grid view
This series investigates the growing interest from the pharmaceutical industry in cannabinoids. In this first piece, we hear from industry experts about the current situation of the ingredient on the pharmaceutical market.
Researchers use the Earth’s biodiversity for pharmaceuticals, but this is under threat due to climate change and habitat destruction. The Nagoya Protocol aims to conserve these resources in a sustainable way.
A new process developed by the University of Bath protects a TB antigen and a novel vaccine adjuvant from heat damage.
The US supply of heparin, an ingredient used in anticoagulant drugs and found in pigs, is under threat due to an outbreak of disease in Chinese herds.
Researchers have developed a model that describes how antibody solutions separate into different phases and could be used to anticipate the stability and shelf-life of drugs.
A vaccine containing the DNA of HIV is poised to enter a Phase II trial, making it the first vaccine of its kind to do so.
The FDA has handed a CRL to Biohaven for its ALS treatment awaiting approval due to concerns regarding the medication’s API.
The FDA has released draft guidance for using the Inactive Ingredients Database to aid drug developers.
A study has shown that crystallising drugs removes localised immune reaction, allowing long-term release of drugs from medical devices.
The filler market is predicted to increase to US$2 billion by 2024, according to a new report.
Substandard and counterfeit drugs can negatively impact the pharmaceutical industry and patients. Here, we investigate counterfeits in south-east Asia and possible solutions.
New digital design and manufacturing techniques offer pharmaceutical manufacturers the possibility of a systems-based, digital approach to substantially streamline their design, development and manufacturing processes. The ADDoPT collaborative consortium has been working to explore how emerging process understanding and predictive models can be applied and embedded within industrial workflows to…
Nature can offer inspiration for the synthesis of more effective drug delivery platforms. In this article, Marc Baiget Francesch discusses the potential of capsosomes as a novel, biocompatible, drug delivery system.
Researchers have discovered the formulation of glucagon fibrils, which could inform drug formulation for diabetic patients.
Researchers have developed a method of creating stable nanoemulsions which could be used in new drug delivery processes.
